← Back

Wire · operational-macro

FDA announces HBV drug approval, GLP-1 receptor agonist warning

Published

20 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at acpjournals.org →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

The FDA approved bepirovirsen injection as the first antisense oligonucleotide treatment for certain chronic hepatitis B patients without cirrhosis and added boxed warnings for serious liver reactions. It also granted accelerated approval to dostarlimab for specific rectal cancer cases and mandated a new safety warning for GLP-1 receptor agonists regarding potential optic nerve damage.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face tighter regulatory scrutiny on liver safety in HBV drugs and new entry points in rectal cancer treatment approvals. This shift opens a compliance gate while raising risks in GLP-1 therapies that you must manage.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-approvalhepatitis-bGLP-1cancer-treatmentdrug-safety